Montelukast Dosage for a 7-Year-Old
For a 7-year-old child, the appropriate dose of montelukast (Singulair) is 5 mg once daily, administered as a chewable tablet. 1, 2
Age-Specific Dosing
The FDA-approved dosing for montelukast is stratified by age, and a 7-year-old falls into the 6-14 years age group 2:
- Children 6 to 14 years of age: One 5 mg chewable tablet once daily 1, 2
- Children 2 to 5 years of age: One 4 mg chewable tablet or oral granules once daily 1, 2
- Adolescents ≥15 years and adults: One 10 mg tablet once daily 1, 2
Administration Guidelines
Timing and Food: For asthma treatment, montelukast should be administered once daily in the evening, with or without food 2. For allergic rhinitis, the time of administration can be individualized without regard to meals 2.
Important Administration Points:
- If a dose is missed, the next dose should be taken at the regular time—never double dose 2
- The 5 mg chewable tablet provides systemic exposure similar to the 10 mg adult dose, based on pharmacokinetic studies 2, 3
- Clinical trials have not evaluated morning versus evening dosing efficacy in asthma, but evening administration is the standard recommendation 2
Clinical Context and Warnings
FDA Boxed Warning: The FDA issued a boxed warning for montelukast in March 2020 regarding serious neuropsychiatric events, including agitation, depression, sleep disturbances, suicidal thoughts and behavior 4, 2. These events have been reported in pediatric patients with and without prior psychiatric history 2.
Treatment Positioning: According to NAEPP guidelines, montelukast is positioned as an alternative therapy (not preferred) for mild persistent asthma in children 5-11 years old 5. Inhaled corticosteroids remain the preferred first-line controller therapy 5, 1. For allergic rhinitis, montelukast should be reserved for patients with inadequate response or intolerance to alternative therapies 2.
Efficacy Considerations
The 5 mg dose in children 6-14 years has demonstrated:
- Significant improvements in FEV₁ (primary outcome) over 8 weeks 6
- Reductions in β-agonist use and asthma exacerbations 6
- Onset of action within 1 day in most patients 6
- Better compliance compared to inhaled therapies due to once-daily oral administration 6, 7
However, when compared head-to-head with inhaled fluticasone in the MOSAIC study, montelukast was not superior and showed higher rates of systemic corticosteroid use and asthma attacks 8.
Safety Profile
Montelukast is generally well tolerated in children 1, 6. Common adverse events include:
Critical Safety Caveat: Given the neuropsychiatric risks, prescribers must discuss benefits and risks with patients and caregivers, advising them to monitor for behavioral changes 2. Recent large observational data from Sweden found no increased risk of neuropsychiatric events in children using montelukast versus long-acting β-agonists 11, though the FDA warning remains in effect.